Fetuin-A as a biomarker to predict invasive Pneumococcal disease in children  by Janapatla, R.P. et al.
17th International Congress on Infectious Diseases / International Journal of Infectious Diseases 45S (2016) 1–477 153
Results: Of 501 serum samples, 290 (58%)were found to be pos-
itive for any agglutinin. However, 97.5% of the positive sera had O,
H, and AH agglutinin titres less than or equal to 80, 160 and 80
respectively. The rate of H and AH agglutinin positivity was sig-
niﬁcantly higher in females with a baseline titre for AH agglutinin
of 160 (versus 80 in males). Test positivity rates for all agglutinins
was lower in the population below 20 years but this was statisti-
cally signiﬁcant only for O agglutinins. O agglutinin positivity rates
remained steady after the age of 20 while H positivity rates rose
with age.
Conclusion: The study shows that though the background
prevalence of Salmonella O, H and AH agglutinins in the healthy
population in Sri Lanka is high, they are found at low titres, with
baseline titres of Salmonella Typhi O, Salmonella Typhi H, and
Salmonella Paratyphi AH agglutinins being 80, 160 and 80 respec-
tively. Therefore the Widal test can still be used as a tool for the
diagnosis of enteric fever. It is important to consider sex and age
when interpreting a positive test and determining cut off titres for
acute infection.
http://dx.doi.org/10.1016/j.ijid.2016.02.367
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Background: Streptococcus pneumoniae, a neuraminidase-
producing pathogen, can cause invasive pneumococcal disease
(IPD) with or without hemolytic uremic syndrome (HUS) in
humans.We aimed to identify abundant serumasialoglycoproteins
after pneumococcal neuraminidase treatment. We hypothesized
that serum sialoglycoproteins such as fetuin-A can serve as a
biomarker to predict IPD or HUS.
Methods&Materials:We constructed serum sialoglycoprotein
proﬁles before and after pneumococcal neuraminidase treatment
using proteomic approach. We analyzed the clinical characteristics
and serum samples from 46 pediatric patients with pneumococ-
cal infection to verify the predictive role of fetuin-A in IPD. Serum
fetuin-A levels were determined by enzyme-linked immunosor-
bent assay.
Results: Fetuin A was identiﬁed after neuraminidase treat-
ment and lectin capture. Bovine fetuin inhibited the activity of
neuraminidases with IC50 at 2.59 mg/mL for NanA, 2 mg/mL for
NanB and 1.2 mg/mL for NanC. Mean fetuin-A levels in the HUS
patients was signiﬁcantly lower (207±80 mg/L, p<0.001) than in
patients with lobar pneumonia (610±190 mg/L) as well as the
healthy controls (630±250 mg/L). In comparing HUS with necro-
tizing pneumonia and lobar pneumonia, the ROC area under the
curve was 0.842; a cutoff value of 298 mg/L yielded sensitivity
of 92.9% (95% CI: 68.5%–98.7%) and speciﬁcity of 71.9% (95% CI:
54.6%-84.4%).
Conclusion: By qualitative and quantitative analysis of serum
fetuin-A in pneumococcal infections, we may identify complicated
pneumonia with or without HUS caused by S. pneumoniae. Serial
measurements of fetuin-A also has the potential to reﬂect patients’
response to therapy and recovery from IPD. We recommend addi-
tion of fetuin-A to the panel of biomarkers currently used for severe
IPD.
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Background: Tuberculosis (TB) is one of the public health crisis
caused by Mycobacterium tuberculosis complex. The emergence of
multi-drug resistant TB (MDR-TB) and extensively drug resistant
TB (XDR-TB) has affected disease management. There is a need for
rapid, accurate diagnosis of TB and initiation of appropriate treat-
ment.We have performedwhole genome analysis for evaluation of
drug resistance conferring mutations early in the clinical isolates
from patients who fail Anti-tubercular treatment (ATT).
Methods & Materials: Clinical data and sputum samples were
collected from patients who were attending a tertiary care centre
with risk factors for drug resistant tuberculosis. Smearmicroscopy,
culture (LJmedia) and PCR (IS6110 / TRC4primers)were performed
to identify Mycobacterium tuberculosis (MTB). Culture isolates from
patient samples were subjected to whole genome sequence anal-
ysis by Next generation sequencing technique (NGS) using Miseq,
Illumina platform and the corresponding drug resistant mutations
were analysed using bioinformatics databases such as TB-Proﬁler,
TBDReaM.
Results: A total of ﬁve clinical isolates were subjected to whole
genomesequenceanalysisbyNGS technique.Ofwhich, two isolates
were from patients with pulmonary TB, who were treatment fail-
ure cases (one failed Category-1 and one failed Category-2ATT) and
considered for MDR-TB were enrolled in this study. Whole genome
analysis of the ﬁrst possible culture isolate after treatment failure
in both strains showed evidence of high level drug resistance to
Rifampicin with mutations in rpoB gene at codon L511P, S531L and
for Isoniazid with mutations in katG gene at codon S315G. One iso-
late (failed Category-1 ATT) had high conﬁdence drug resistance
conferring mutation in embB gene at codon Q497R corresponding
to Ethambutol resistance. Some major drug resistant mutations to
Fluoroquinoloneswere observed in gyrA gene (E21Q, S95T, G668D)
in both genomes. Other non-synonymous substitutions were also
observed in aphC gene at W53L (Isoniazid), oxyR gene at L13F (Iso-
niazid) and gyrB gene at M291I (Fluoroquinolones).
